Modulation of p53 signalling and response to MDM2-p53 binding antagonists
Mutational inactivation of the p53 tumour suppressor protein, encoded by the TP53 gene, occurs in ≈50% of malignancies overall. Non-genotoxic activation of p53 signalling in the remaining TP53 wild-type malignancies is a promising therapeutic strategy. MDM2 inhibitors, such as Nutlin-3 and RG7388, c...
| Main Author: | |
|---|---|
| Published: |
University of Newcastle upon Tyne
2016
|
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.701153 |